43 results about "Thyroid cancer cell" patented technology

A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. The compounds' ability to inhibit RET kinase is quantified, i.e., their respective RET IC50 and EC50 values are described. One such compound, known as cyclobenzaprine and herein as SW-01, has been identified as RET-specific with an IC50 of 300 nM. SW-01 inhibits RET autophosphorylation and blocks the growth and transformation of thyroid cancer cell lines. It has been further tested in pancreatic cancer, breast cancer, and SCLC cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells.

We examined IQGAP1 copy gain and its relationship with clinicopathologic outcomes of thyroid cancer and investigated its role in cell invasion and molecules involved in the process. We found IQGAP1 copy number (CN) gain ?3 in 1 of 30 (3%) of benign thyroid tumor, 24 of 74 (32%) follicular variant papillary thyroid cancer (FVPTC), 44 of 107 (41%) follicular thyroid cancer (FTC), 8 of 16 (50%) tall cell papillary thyroid cancer (PTC), and 27 of 41 (66%) anaplastic thyroid cancer, in increasing order of invasiveness of these tumors. A similar tumor distribution trend of CN ?4 was also seen. IQGAP1 copy gain was positively correlated with IQGAP1 protein expression. It was significantly associated with extrathyroidal and vascular invasion of FVPTC and FTC and, remarkably, a 50%-60% rate of multifocality and recurrence of BRAF mutation-positive PTC (P=0.01 and 0.02, respectively). The siRNA knock-down of IQGAP1 dramatically inhibited thyroid cancer cell invasion and colony formation. Co-immunoprecipitation assay showed direct interaction of IQGAP1 with E-cadherin, a known invasion-suppressing molecule, which was upregulated when IQGAP1 was knocked down. IQGAP1, through genetic copy gain, plays an important role in the invasiveness of thyroid cancer and represents a useful prognostic marker and therapeutic target for this and other cancers.

The invention discloses a traditional Chinese medicine preparation for treating thyroid cancer, and belongs to the technical field of medicines for treating thyroid cancer. The traditional Chinese medicine preparation is prepared from wolfiporia extensa, codonopsis pilosula, loranthus parasiticus, lentinus edodes, red beans, the root bark of white mulberry, the bark of eucommia, akebiaquinata, lignum dalbergiae odoriferae, bighead atractylodes rhizome, fiveleaf akebia fruits, arisacma consanguineum, pawpaw, hairyvein agrimony, semen coicis, garden burnet, cynanchum glaucescens, Chinese lobelia, folium cycas, hedyotis diffusa, indigo naturalis, cinnamon, subprostrate sophora, polygala tenuifolia, rhizoma alismatis, honeysuckle, panax notoginseng, peach kernels, centipedes and a Chinese starjasmine stem. The traditional Chinese medicine preparation is obtained through reasonable and scientific compatibility of the Chinese herbal medicines, the medicine effects complement each other and directly reach the focus depth place, transfer and spreading of thyroid cancer cells are effectively controlled, meanwhile, the immunologic function of the human body can be enhanced, growth of cancer cells is restrained, and no toxic or side effect is produced; lumps can be reduced within a short period of time, transfer is controlled, pain is relieved, the illness state is stabilized, the life time is prolonged, and clinical cure is achieved; the medicine property is gentle, and the traditional Chinese medicine preparation is gentle, and easy and convenient to take.

The invention discloses a poorly differentiated thyroid cancer cell line PDTC-1 and applications thereof. The cell line is a poorly differentiated thyroid cancer cell line, and the accession number thereof is CGMCC No. 4939. The present invention establishes a poorly differentiated thyroid carcinoma cell line, successfully establishes a nude-mouse transplanted tumor model by using the cell line, provides a screenable cell line for the study of thyroid cancer cytology, and the cell line can be used for establishing important models for screening thyroid cancer-sensitive chemotherapy drugs. On the basis of the present invention, differences of differentiated, poorly differentiated and undifferentiated thyroid cancers can be studied from the genetic level and the protein level, having important meaning for elucidating the generating mechanism and finding therapeutic targets of the thyroid cancer. The cell line of the present invention provides a platform for the study of thyroid cancer evolution and biological characteristics of poorly differentiated cancers, and is conducive to the in-depth study of pathogenesis, metastasis and recurrence of thyroid cancer.

The invention belongs to the technical field of pharmacy, and provides triptolide derivatives, and a preparation method and applications thereof. The structural formula of triptolide derivatives is represented in the description, and R represents an amine ring compound group, more specifically, a cyclohexane group, a morpholine group, or an aniline group. The preparation method comprises followingsteps: taking triptolide as the raw material, adding an amine ring reagent and a catalyst into triptolide, wherein the mole ratio of triptolide to the amine ring reagent is 1:1-6, and the mole ratioof triptolide to the catalyst is 1:0.1-0.4; carrying out reactions for 24-48 hours in the absence of solvent; after reactions, carrying out a post treatment: washing the reaction liquid by ethyl acetate, then washing the ethyl acetate phase by deionized water for many times, drying, dehydrating, and drying; and purifying triptolide derivates: adopting an adsorbent as a stationary phase to carry out separation and purification, and recovering and drying the eluent to obtain triptolide derivates. The triptolide derivates can inhibit thyroid cancer cells, human prostatic cancer cells, and colon cancer cells.

The invention belongs to the field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine composition for treating thyroid cancer and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following nine raw medicinal materials: astragalus membranaceus, bighead atractylodes rhizome, poria cocos, white paeony root, prepared arisaema consanguineum schott, thunberg fritillary bulb, pinellia ternate, oroxylum indicum and selfheal, and has the effects of invigorating spleen and replenishing qi, eliminating dampness and phlegm, and softening hardness to dissipate stagnation. Pharmacodynamic experiment results show that the traditional Chinese medicine composition disclosed by the invention can obviously inhibit the growth of human thyroid cancer tumors in nude mice bearing tumors and obviously inhibit the proliferation of thyroid cancer cells in vitro, has an exact treatment effect on thyroid cancer, and provides a new clinical medication choice for patients.

A novel chordin-like polypeptide is found out in a protein secreted from mesenchymal stem cells. This polypeptide is useful as a cancer marker and a remedy for parotid cancer, lung cancer, esophagus cancer, gastric cancer, duodenal carcinoma, kidney cancer, ureteral cancer, testicular cancer, ovarian cancer, uterine cancer, leukemia, intestinal cancer, colon cancer, rectal cancer, biliary cancer or thyroid cancer cells, etc. Moreover, it is found out that the above polypeptide has an activity of modulating bone differentiation. Thus, this polypeptide is also useful as a bone disease marker and a remedy for bone diseases such as arthritis deformans, rheumatoid arthritis and osteoporosis.

The invention relates to a gene related to papillary thyroid cancer and its application. According to the base sequence of the gene, real-time quantitative PCR primers are designed and synthesized, and the long-chain non-coding transcribed by the gene is detected in clinical case samples of papillary thyroid cancer. The expression level of RNA was found to be significantly down-regulated in papillary thyroid tumor tissue, and gene silencing of the long non-coding RNA could significantly promote the growth of thyroid cancer cells. The invention is expected to prepare preparations for auxiliary diagnosis, gene therapy, curative effect prediction or prognosis judgment of papillary thyroid cancer.

A halogenated dideoxy sugar derivative, having the following general structure I wherein X is halogen,R1 and R2 are H or Br; R3 and R4 are OH or OAc. The compounds 1-14 of the current invention has strong inhibition effect on human nasopharyngeal cancer CNE-2Z cells, human lung cancer A549 cells. human colon cancer HT-29 cells, human liver cancer Bel-7402 cells, human rectum cancer cells HCE 8693, human stomach cancer BGC-803 cells, human esophagus cancer CaEs-17 cells, human breast cancer cells MCF-7, human ovarian cancer cells A2780, pancreatic cancer cells PC-3, human bladder cells EJ, human brain glia cells TG-905, human leukemia cells K562, human melanoma M 14 cells and human anaplastic thyroid carcinoma TA-K cells. They can be used to prepare anti-tumor medicament and have significant clinic value.

The invention discloses a PCR-specific primer, a kit and a use method thereof for detecting genes related to metastasis of thyroid cancer. The high-throughput sequencing technology-based PCR-specific primers for the detection of thyroid cancer metastasis-related genes independently developed by the present invention, the kit and the use method involved in the thyroid cancer metastasis-related genes have been verified by samples and can be used to detect thyroid cancer The mutation status of metastasis-related genes, the test result can be used as an intermediate result together with other test results to determine whether cancer cells have metastasized or whether there is a possibility of metastasis or recurrence, which is of great significance for the treatment and prognosis of thyroid cancer. Moreover, the present invention uses high-throughput gene sequencing technology to break through the limitations of traditional detection technology, improves detection sensitivity, and can detect even low-abundance mutated genes, thereby helping to predict the possibility of proliferation and recurrence of thyroid cancer cells. Significance.

The invention discloses a traditional Chinese medicine composition with antithyroid cancer activity, its preparation method and its application. The traditional Chinese medicine compound composition consists of 20-60 parts of Solanum solanum, 12-36 parts of Radix Ginseng, and 10-30 parts of Ophiopogon japonicus , 15 to 45 parts of Prunella vulgaris, 15 to 45 parts of Shanzi mushroom, and 10 to 30 parts of August Zha. Experimental results show that the traditional Chinese medicine composition with anti-thyroid cancer activity provided by the present invention has scientific and reasonable proportioning, rigorous medication, and has the effects of anti-cancer and detoxification, reducing phlegm and blood stasis, nourishing qi and nourishing yin, etc. It has a strong killing effect, can promote the production of tumor necrosis factor, improves the immunity of tumor patients, and has high safety and low toxic and side effects. The preparation method provided by the invention has stable quality, high content of extracted active ingredients, strong operability, and is suitable for large-scale industrial production.

The invention belongs to the technical field of artificial cultivation of edible fungi, particularly relates to an artificially cultivated phellinus igniarius sporocarp extract for treating thyroid cancer, and further discloses a preparation method of the artificially cultivated phellinus igniarius sporocarp extract. The artificially cultivated phellinus igniarius sporocarp extract for treating the thyroid cancer is obtained by taking phellinus igniarius sporocarp as a raw material for carrying out water body and alcohol precipitation extraction, the obtained extract has the effects of supporting body resistance and promoting immune functions, has an obvious inhibiting effect on in-vivo transplantation of nude mice with human thyroid cancer, can obviously inhibit proliferation of thyroid cancer cells in vitro at the same time, has a good thyroid cancer treatment effect, can relieve the pain of a tumor patient, prolongs the lifetime, improves the life quality of the patient, and bringsa new candidate medicine for treating the thyroid cancer to clinical application, and the extract is a natural extract, and has the advantages of being high in medication safety and low in toxic and side effects.

The invention belongs to the field of tumor molecular biology and particularly relates to application of an XPR1 inhibitor in preparation of a product for inhibiting migration and / or proliferation of thyroid cancer cells. The invention finds that the expression of an XPR1 gene in the thyroid cancer cells is obviously higher than that of normal thyroid cells, and the influence of the XPR1 gene on the migration and proliferation capacity of the thyroid cancer cells is verified through a CCK-8 experiment, a colony formation experiment, a Transwell migration experiment, a Matrigel invasion experiment, a flow cytometry, a cell apoptosis experiment and a Western blot experiment. The invention finds that the migration and proliferation capacity of the thyroid cancer cells can be effectively lowered by knocking down the expression of the XPR1 gene.